Veracyte’s cash-generative, clinically validated cancer-testing franchises fund a multi-analyte expansion, with a $75.71 probability-weighted five-year target offset by reimbursement and launch execution risks.
Overview
Veracyte is a commercial-stage cancer diagnostics company whose centralized CLIA laboratories perform proprietary genomic tests, with testing accounting for more than 95% of sales and 97% in Q2 2026. Afirma and Decipher anchor thyroid and urology franchises; Prosigna, TrueMRD and acquired UroAmp extend the platform into breast cancer and blood- and urine-based bladder testing. Clinical validation, NCCN guideline inclusion, coverage across more than 270 million insured U.S. lives and physician workflow integration support a defensible position. **Q2 2026 revenue grew 15% to $150.3 million, with testing revenue up 19% and adjusted EBITDA margin expanding to 29.2%.** Management raised 2026 revenue guidance to $590–$596 million, implying 14%–15% growth, and reaffirmed Adjusted EBITDA margin above 26%. The company reported $25.5 million of GAAP net income, $45.8 million of quarterly operating cash flow and zero funded debt. At approximately $45.43 per share, valuation was 23.2x forward non-GAAP P/E and 5.76x EV/TTM revenue. The report’s probability-weighted FY2031 target is $75.71, with near-term catalysts including Prosigna and TrueMRD adoption and UroAmp’s planned late-2028 launch; reimbursement and execution remain key constraints.